(Q48000888)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22433185%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

title

Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22433185%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22433185%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

David Michelson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22433185%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Richard Hargreaves

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22433185%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Robert Alexander

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22433185%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Paulette Ceesay

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22433185%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Christopher Lines

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22433185%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Scott Reines

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22433185%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

publication date

20 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22433185%20AND%20SRC:MED&resulttype=core&format=json

The International Journal of Neuropsychopharmacology

26 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22433185%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22433185%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22433185%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

1-11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22433185%20AND%20SRC:MED&resulttype=core&format=json

The hospital anxiety and depression scale

26 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

Clinical biomarkers in drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

Tachykinin receptors as therapeutic targets in stress-related disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

The assessment of anxiety states by rating

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

Central tachykinins: mediators of defence reaction and stress reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

Testing for qualitative interactions between treatment effects and patient subsets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

Synthesis and characterization of a potent, selective, radiolabeled substance-P antagonist for NK1 receptor quantitation: ([18F]SPA-RQ).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

REPLICATION OF FACTORS OF PSYCHOPATHOLOGY IN INTERVIEW, WARD BEHAVIOR AND SELF-REPORT RATINGS OF HOSPITALIZED DEPRESSIVES

21 January 2018

2 references

https://api.crossref.org/works/10.1017%2FS1461145712000065

21 January 2018

https://api.crossref.org/works/10.1017%2FS1461145712000065

7 January 2021

Use of NK1 receptor antagonists in the exploration of physiological functions of substance P and neurokinin A.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

Evidence for a tonic facilitatory influence of substance P on dopamine release in the nucleus accumbens

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

Simplified reference tissue model for PET receptor studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

Pharmacological treatment of generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

7 January 2021

First-line pharmacotherapy approaches for generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

7 January 2021

Neurotransmitter functions of mammalian tachykinins

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

7 January 2021

The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000065

7 January 2021

10.1017/S1461145712000065

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22433185%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference